Hematologic Malignancy
Erythroid Neoplasm
CI-CAN-00000851Explore in graph →
Hematologic48 active trials2 approved drugs2 evidence items
- NCIt
- C7064
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000851Explore in graph →
Clinical trials
260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (50)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07839858 | A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment of Second-line Polycythemia Vera in France(VeRavie) | completed | — | 237 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT01831635 | Myeloproliferative Neoplasms: an In-depth Case-control Study(MOSAICC) | completed | — | 234 | Queen's University, BelfastOTHER |
| 1 |
| Sep 11, 2026 |
| clinicaltrials |
| NCT02071901 | Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy | completed | Phase 2 | 31 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT00093470 | Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission | completed | Phase 3 | 144 | National Cancer Institute (NCI)NIH | 3 | Jul 14, 2026 | clinicaltrials |
| NCT06752941 | LOW-PV Continuation(CONT-LOW-PV) | completed | — | 36 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETSOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT02493530 | TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea | completed | Phase 1 | 60 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05558696 | A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004) | completed | Phase 2 | 20 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)INDUSTRY | 3 | May 7, 2026 | clinicaltrials |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT01787487 | Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm | completed | Phase 2 | 121 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT00255346 | Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | completed | Phase 2 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT01760655 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies | completed | Phase 2 | 62 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT04182100 | Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply | completed | Phase 2 | 29 | PharmaEssentia Japan K.K.INDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04057040 | Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) | completed | Phase 2 | 70 | Protagonist Therapeutics, Inc.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT01822015 | Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Early Phase 1 | 55 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT00588991 | Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2025 | clinicaltrials |
| NCT02085408 | Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 3 | 727 | ECOG-ACRIN Cancer Research GroupNETWORK | 3 | Dec 13, 2024 | clinicaltrials |
| NCT06002490 | A Study to Evaluate P1101 in Japanese PV Patients | completed | Phase 3 | 21 | PharmaEssentia Japan K.K.INDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT03003325 | The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV(Low-PV) | completed | Phase 2 | 127 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06134102 | Clinical and Laboratory Characteristics of Polycythemia Vera(PV-ARC) | completed | — | 1,150 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT04243122 | Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients(AIRPORT-MPN) | completed | Phase 2 | 44 | Ottawa Hospital Research InstituteOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05853445 | A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera(PAVE) | completed | — | 467 | Novartis PharmaceuticalsINDUSTRY | 1 | May 6, 2024 | clinicaltrials |
| NCT06371573 | Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms | completed | — | 45 | Federico II UniversityOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04767802 | PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit(PACIFIC) | completed | Phase 2 | 20 | Protagonist Therapeutics, Inc.INDUSTRY | 2 | Mar 18, 2024 | clinicaltrials |
| NCT01823198 | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | completed | Phase 1 / Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT01816256 | Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms | completed | N/A | 102 | University Health Network, TorontoOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT04051307 | Dual Vaccine Trial in Myeloproliferative Neoplasms | completed | Phase 1 / Phase 2 | 9 | Inge Marie SvaneOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT02124746 | Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia | completed | Phase 2 | 87 | Sierra Oncology LLC - a GSK companyINDUSTRY | 5 | Jun 18, 2023 | clinicaltrials |
| NCT02098161 | LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT03895112 | MPN-RC 118 AVID200 in Myelofibrosis | completed | Phase 1 | 21 | John MascarenhasOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT02556931 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | completed | Phase 2 | 117 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT04424147 | Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML | completed | Phase 2 | 96 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT01555268 | Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT01168219 | Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05421104 | Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea. | completed | — | 1,576 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 5, 2022 | clinicaltrials |
| NCT01387763 | A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms(DALIAH) | completed | Phase 3 | 202 | Thomas Stauffer LarsenOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT01423851 | Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF | completed | Phase 1 / Phase 2 | 77 | NS Pharma, Inc.INDUSTRY | 1 | Mar 9, 2022 | clinicaltrials |
| NCT00352365 | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2022 | clinicaltrials |
| NCT00369317 | Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 3 | 205 | Children's Oncology GroupNETWORK | 4 | Jan 28, 2022 | clinicaltrials |
| NCT01981850 | A Phase 2 Study of RO7490677 In Participants With Myelofibrosis | completed | Phase 2 | 125 | Hoffmann-La RocheINDUSTRY | 8 | Jan 5, 2022 | clinicaltrials |
| NCT00038675 | Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate | completed | N/A | 125 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT02144675 | Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia | completed | Phase 2 | 27 | Rutgers, The State University of New JerseyOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT02038036 | Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.(RESPONSE-2) | completed | Phase 3 | 149 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 20, 2021 | clinicaltrials |
| NCT03065400 | PD-1 Inhibition in Advanced Myeloproliferative Neoplasms | completed | Phase 2 | 10 | John MascarenhasOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT02218047 | AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.(CONTI-PV) | completed | Phase 3 | 170 | AOP Orphan Pharmaceuticals AGINDUSTRY | 12 | Jun 1, 2021 | clinicaltrials |
| NCT02912884 | Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure(MPNClot) | completed | — | 80 | Dr Yan BeauverdOTHER | 2 | Nov 10, 2020 | clinicaltrials |
| NCT01235572 | Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy | completed | Phase 2 | 200 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT02823184 | Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms(PhiNESS) | completed | — | 148 | University Hospital, BordeauxOTHER | 1 | Jun 19, 2020 | clinicaltrials |
| NCT01839240 | Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | May 15, 2020 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials